A share price of X4 Pharmaceuticals Inc [XFOR] is currently trading at $0.96, up 0.99%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The XFOR shares have gain 3.61% over the last week, with a monthly amount glided 13.54%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 1, March 2024, X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). In a post published today on Yahoo Finance, X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on February 29, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 1,524,112 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.
From an analyst’s perspective:
X4 Pharmaceuticals Inc [NASDAQ: XFOR] stock has seen the most recent analyst activity on December 12, 2023, when B. Riley Securities downgraded its rating to a Neutral and also revised its price target to $1 from $3. On December 22, 2022, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $3 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $3 on December 12, 2022. Oppenheimer initiated its recommendation with a Outperform and recommended $20 as its price target on December 23, 2019. ROTH Capital started tracking with a Buy rating for this stock on December 18, 2019, and assigned it a price target of $20. In a note dated December 09, 2019, Citigroup upgraded an Buy rating on this stock and boosted its target price from $16 to $20.
X4 Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $0.57 and $2.58. Currently, Wall Street analysts expect the stock to reach $3.67 within the next 12 months. X4 Pharmaceuticals Inc [NASDAQ: XFOR] shares were valued at $0.96 at the most recent close of the market. An investor can expect a potential return of 282.29% based on the average XFOR price forecast.
Analyzing the XFOR fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.79, Equity is -2.17 and Total Capital is -0.69. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.86.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9391 points at the first support level, and at 0.9146 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.9840, and for the 2nd resistance point, it is at 1.0044.
X4 Pharmaceuticals Inc [XFOR] reported earnings per share of -$0.01 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.15/share, meaning a difference of $0.14 and a surprise factor of 93.30%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.33 per share as compared to estimates of -$0.16 per share, a difference of -$0.17 representing a surprise of -106.20%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for X4 Pharmaceuticals Inc [NASDAQ:XFOR] is 5.81. Further, the Quick Ratio stands at 5.81, while the Cash Ratio is 5.17.
Transactions by insiders
Recent insider trading involved Mostafa Adam S., Chief Financial Officer, that happened on Feb 12 ’24 when 27721.0 shares were sold. President and CEO, Ragan Paula completed a deal on Feb 12 ’24 to sell 21695.0 shares. Meanwhile, Chief Operating Officer DiBiase Mary sold 3683.0 shares on Feb 12 ’24.
